TOP TEN perturbations for NM_000037 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000037
Selected probe(set): 205391_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000037 (205391_x_at) across 5392 perturbations tested by GENEVESTIGATOR:

basal cell carcinoma study 3 / normal epidermal keratinocytes

Relative Expression (log2-ratio):3.501361
Number of Samples:4 / 2
Experimental basal cell carcinoma study 3
Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC).
Control normal epidermal keratinocytes
Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37?C in humidified air containing 5% CO2.

tetanus toxin study 1 / cytomegalovirus study 1

Relative Expression (log2-ratio):2.3457747
Number of Samples:3 / 3
Experimental tetanus toxin study 1
Peripheral blood mononuclear cell samples from healthy, HIV-negative individuals were CFSE labeled and stimulated with tetanus toxoid (tetanospasmin) for 6 days. CFSE-low and pathogen-specific CD4+ T cell samples were isolated by FACS sorting from stimulated PBMC?s.
Control cytomegalovirus study 1
Peripheral blood mononuclear cell samples from healthy, HIV-negative individuals were CFSE labeled and stimulated with CMV-antigens (lysate) for 6 days. CFSE-low and pathogen-specific CD4+ T cell samples were isolated by FACS sorting from stimulated PBMC?s.

strabismus study 1 / normal extraocular medial rectus muscle tissue

Relative Expression (log2-ratio):-2.241252
Number of Samples:3 / 4
Experimental strabismus study 1
Human extraocular medial rectus muscle tissue sample obtained from patients with strabismus after strabismus correction surgery.
Control normal extraocular medial rectus muscle tissue
Postmortem human extraocular medial rectus tissue samples from healthy donors without any ophthalmologic disease.

cytomegalovirus study 1 / C. albicans study 1

Relative Expression (log2-ratio):-2.1229725
Number of Samples:3 / 3
Experimental cytomegalovirus study 1
Peripheral blood mononuclear cell samples from healthy, HIV-negative individuals were CFSE labeled and stimulated with CMV-antigens (lysate) for 6 days. CFSE-low and pathogen-specific CD4+ T cell samples were isolated by FACS sorting from stimulated PBMC?s.
Control C. albicans study 1
Peripheral blood mononuclear cell samples from healthy, HIV-negative individuals were CFSE labeled and stimulated with Candida albicans-antigens (sonicate) for 6 days. CFSE-low and pathogen-specific CD4+ T cell samples were isolated by FACS sorting from stimulated PBMC?s.

sickle cell disease study 2 (Pax) / normal blood sample

Relative Expression (log2-ratio):2.0228662
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Pax)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene? Blood RNA System Kit followed by an on-column DNase digestion step.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step.

myotonic dystrophy study 2 (DM1) / normal skeletal muscle tissue

Relative Expression (log2-ratio):1.9099302
Number of Samples:10 / 6
Experimental myotonic dystrophy study 2 (DM1)
Muscle biopsies from patients with myotonic dystrophy type 1 (DM1). The disease was diagnosed by DNA mutation testing.
Control normal skeletal muscle tissue
Muscle biopsies from normal individuals.

immunoglobulin (IVIG) study 1 (responder) / Kawasaki disease study 1

Relative Expression (log2-ratio):1.8275414
Number of Samples:6 / 4
Experimental immunoglobulin (IVIG) study 1 (responder)
Whole blood samples from subjects with Kawasaki disease treated with intravenous immunoglobulin therapy (IVIG; 2g/kg). The IVIG were infused over 24 hours as initial therapy between illness days 2 and 6 (median 5.5). The blood samples were obtained 36 hours after the end of intravenous application of immunoglobulins. Patients had good response to the therapy. ATC code:---
Control Kawasaki disease study 1
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy between illness days 2 and 6 (median 5.5). The subjects showed later positive response to intravenous immunoglobulin therapy (IVIG; 2g/kg).

systemic lupus erythematosus study 3 / normal blood sample

Relative Expression (log2-ratio):-1.8102579
Number of Samples:89 / 30
Experimental systemic lupus erythematosus study 3
Blood samples derived from patients with anti-ribonuclear protein-positive (anti-RNP+) systemic lupus erythematosus (SLE).
Control normal blood sample
Blood samples from healthy individuals.

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-1.7984838
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

T-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-1.7670689
Number of Samples:174 / 74
Experimental T-ALL study 1
Bone marrow samples of patients with T-ALL.
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.